Wood N L, Kitces E N, Blaylock W K
Department of Dermatology, Medical College of Virginia-Virginia Commonwealth University, Richmond 23298.
Arch Dermatol. 1990 Jul;126(7):907-13.
Peripheral blood mononuclear cells from 24 patients with mycosis fungoides were used to generate lymphokine activated killer (LAK) cells in vitro by culturing with recombinant interleukin 2. Patients with stage la mycosis fungoides were capable of generating normal levels of LAK cell activity, while patients with more active disease (stages IB to IV) had depressed LAK activity. The ability of these patients' cells to respond in a proliferation assay to various mitogens was similar to that of controls, with the exception of patients in the terminal phase of their illness. Patients with active disease who were unable to generate LAK activity were capable of responding in a proliferation assay to interleukin 2. The results of this study suggest that depressed LAK cell activity in patients with mycosis fungoides may serve as an indicator of a more aggressive disease state.
采用重组白细胞介素2体外培养的方法,从24例蕈样肉芽肿患者的外周血单个核细胞中生成淋巴因子激活的杀伤细胞(LAK细胞)。Ia期蕈样肉芽肿患者能够产生正常水平的LAK细胞活性,而病情更活跃(IB至IV期)的患者LAK活性降低。除了处于疾病终末期的患者外,这些患者的细胞在增殖试验中对各种有丝分裂原的反应能力与对照组相似。无法产生LAK活性的活动性疾病患者在增殖试验中能够对白介素2作出反应。本研究结果表明,蕈样肉芽肿患者LAK细胞活性降低可能是疾病更具侵袭性状态的一个指标。